Efficacy of Influenza Vaccination and Tamiflu® Treatment - Comparative Studies with Eurasian Swine Influenza Viruses in Pigs

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Duerrwald, Ralf ^a   Schlegel, Michael ^a   Bauer, Katja ^b   Vissiennon, Théophile ^c   Wutzler, Peter ^b   Schmidtke, Michaela ^b  

^a IDT Biologika GmbH   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

^c Tierpathologie Leipzig   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; RESPIPORC FLU3; SWINE INFLUENZA VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DYSPNEA; FEMALE; FEVER; HISTOPATHOLOGY; INFECTION PREVENTION; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H1N2; MALE; NONHUMAN; SWINE; SWINE INFLUENZA; SWINE INFLUENZA VIRUS; VIRUS PNEUMONIA; VIRUS REPLICATION; VIRUS SHEDDING;

ANIMALS; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; FEMALE; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H1N2 SUBTYPE; INFLUENZA VACCINES; MALE; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; OSELTAMIVIR; SUS SCROFA; SWINE; SWINE DISEASES; VACCINATION; VIRAL PROTEINS; VIRUS REPLICATION;

INFLUENZA A VIRUS; ORTHOMYXOVIRIDAE; SUIDAE; SUS; SWINE INFLUENZA VIRUS;

EID: 84876428535     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061597     Document Type: Article

References (41)

1. WHO (2009) Influenza (Seasonal).
2. Palese P, (2004) Influenza: old and new threats. Nat Med 10: S82-87.
3. Wright PF, Neumann G, Kawaoka Y (2007) Orthomyxoviruses. In: Knipe DM, Howley PM, editors. Fields Virology. Philadelphia, PA, 19106 USA: Lippincott Williams & Wilkins. pp. 1692-1740.
4. Kuntz-Simon G, Madec F, (2009) Genetic and antigenic evolution of swine influenza viruses in Europe and evaluation of their zoonotic potential. Zoonoses Public Health 56: 310-325.
5. Schrader C, Suess J, (2003) Genetic characterization of a porcine H1N2 influenza virus strain isolated in Germany. Intervirology 46: 66-70.
6. Schrader C, Suess J, (2004) Molecular epidemiology of porcine H3N2 influenza A viruses isolated in Germany between 1982 and 2001. Intervirology 47: 72-77.
7. Van Reeth K, Nicoll A, (2009) A human case of swine influenza virus infection in Europe-implications for human health and research. Euro Surveill 14.
8. Zell R, Bergmann S, Krumbholz A, Wutzler P, Duerrwald R, (2008) Ongoing evolution of swine influenza viruses: a novel reassortant. Arch Virol 153: 2085-2092.
9. Zell R, Motzke S, Krumbholz A, Wutzler P, Herwig V, et al. (2008) Novel reassortant of swine influenza H1N2 virus in Germany. J Gen Virol 89: 271-276.
10. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, et al. (2009) Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 325: 197-201.
11. Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, et al. (2009) In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460: 1021-1025.
12. Smith GJ, Vijaykrishna D, Bahl J, Lycett SJ, Worobey M, et al. (2009) Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 459: 1122-1125.
13. Gubareva LV, Trujillo AA, Okomo-Adhiambo M, Mishin VP, Deyde VM, et al. (2010) Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro. Antivir Ther 15: 1151-1159.
14. Nguyen JT, Smee DF, Barnard DL, Julander JG, Gross M, et al. (2012) Efficacy of combined therapy with amantadine, oseltamivir, and ribavirin in vivo against susceptible and amantadine-resistant influenza A viruses. PLoS One 7: e31006.
15. Krumbholz A, Schmidtke M, Bergmann S, Motzke S, Bauer K, et al. (2009) High prevalence of amantadine resistance among circulating European porcine influenza A viruses. J Gen Virol 90: 900-908.
16. Schmidtke M, Zell R, Bauer K, Krumbholz A, Schrader C, et al. (2006) Amantadine resistance among porcine H1N1, H1N2, and H3N2 influenza A viruses isolated in Germany between 1981 and 2001. Intervirology 49: 286-293.
17. Bright RA, Medina MJ, Xu X, Perez-Oronoz G, Wallis TR, et al. (2005) Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366: 1175-1181.
18. Deyde V, Garten R, Sheu T, Smith C, Myrick A, et al. (2009) Genomic events underlying the changes in adamantane resistance among influenza A(H3N2) viruses during 2006-2008. Influenza Other Respi Viruses 3: 297-314.
19. Bauer K, Duerrwald R, Schlegel M, Pfarr K, Topf D, et al. (2011) Neuraminidase inhibitor susceptibility of swine influenza A viruses isolated in Germany between 1981 and 2008. Med Microbiol Immunol 201: 61-72.
20. Bauer K, Schrader C, Suess J, Wutzler P, Schmidtke M, (2007) Neuraminidase inhibitor susceptibility of porcine H3N2 influenza A viruses isolated in Germany between 1982 and 1999. Antiviral Res 75: 219-226.
21. Pensaert M, Ottis K, Vandeputte J, Kaplan MM, Bachmann PA, (1981) Evidence for the natural transmission of influenza A virus from wild ducts to swine and its potential importance for man. Bull World Health Organ 59: 75-78.
22. Scholtissek C, Burger H, Bachmann PA, Hannoun C, (1983) Genetic relatedness of hemagglutinins of the H1 subtype of influenza A viruses isolated from swine and birds. Virology 129: 521-523.
23. Brookes SM, Nunez A, Choudhury B, Matrosovich M, Essen SC, et al. Replication, pathogenesis and transmission of pandemic (H1N1) 2009 virus in non-immune pigs. PLoS One 5: e9068.
24. Lange E, Kalthoff D, Blohm U, Teifke JP, Breithaupt A, et al. (2009) Pathogenesis and transmission of the novel swine-origin influenza virus A/H1N1 after experimental infection of pigs. J Gen Virol 90: 2119-2123.
25. Van Reeth K, Gregory V, Hay A, Pensaert M, (2003) Protection against a European H1N2 swine influenza virus in pigs previously infected with H1N1 and/or H3N2 subtypes. Vaccine 21: 1375-1381.
26. Van Reeth K, Labarque G, De Clercq S, Pensaert M, (2001) Efficacy of vaccination of pigs with different H1N1 swine influenza viruses using a recent challenge strain and different parameters of protection. Vaccine 19: 4479-4486.
27. Van Reeth K, Van Gucht S, Pensaert M, (2003) Investigations of the efficacy of European H1N1- and H3N2-based swine influenza vaccines against the novel H1N2 subtype. Vet Rec 153: 9-13.
28. Weingartl HM, Albrecht RA, Lager KM, Babiuk S, Marszal P, et al. (2009) Experimental infection of pigs with the human 1918 pandemic influenza virus. J Virol 83: 4287-4296.
29. Hsu J, Santesso N, Mustafa R, Brozek J, Chen YL, et al. (2012) Antivirals for Treatment of Influenza: A Systematic Review and Meta-analysis of Observational Studies. Ann Intern Med.
30. Osterholm MT, Kelley NS, Sommer A, Belongia EA, (2011) Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 12: 36-44.
31. Durrwald R, Krumbholz A, Baumgarte S, Schlegel M, Vahlenkamp TW, et al. (2010) Swine influenza A vaccines, pandemic (H1N1) 2009 virus, and cross-reactivity. Emerg Infect Dis 16: 1029-1030.
32. Gauger PC, Vincent AL, Loving CL, Lager KM, Janke BH, et al. (2011) Enhanced pneumonia and disease in pigs vaccinated with an inactivated human-like (delta-cluster) H1N2 vaccine and challenged with pandemic 2009 H1N1 influenza virus. Vaccine 29: 2712-2719.
33. Kyriakes CS, Olsen CW, Carman S, Brown IH, Brookes SH, et al. (2010) Serologic cross-reactivity with pandemic (H1N1) 2009 virus in pigs. European Emerging Infectious Disease 16: 96-99.
34. Van Reeth K, Labarque G, Pensaert M, (2006) Serological profiles after consecutive experimental infections of pigs with European H1N1, H3N2, and H1N2 swine influenza viruses. Viral Immunol 19: 373-382.
35. Francis T, (1960) On the doctrine of original antigenic sin. Proceedings of the American Philisophical Society 104: 572-578.
36. Powers DC, Belshe RB, (1994) Vaccine-induced antibodies to heterologous influenza A H1N1 viruses: effects of aging and "original antigenic sin". J Infect Dis 169: 1125-1129.
37. Xing Z, Cardona CJ, (2009) Preexisting immunity to pandemic (H1N1) 2009. Emerg Infect Dis 15: 1847-1849.
38. Mishin VP, Novikov D, Hayden FG, Gubareva LV, (2005) Effect of hemagglutinin glycosylation on influenza virus susceptibility to neuraminidase inhibitors. J Virol 79: 12416-12424.
39. Kärber G, (1931) Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche [A contribution to the collective treatment of a pharmacological experiment series]. Archiv für experimentelle Ptahologie und Pharmakologie 162: 480-483.
40. Spearman C, (1908) The method of the "right and wrong" cases ("constant stimuli") without Gaus's formulae. British Journal Psychology 2: 227-242.
41. Sandbulte MR, Gao J, Straight TM, Eichelberger MC, (2009) A miniaturized assay for influenza neuraminidase-inhibiting antibodies utilizing reverse genetics-derived antigens. Influenza and other Respiratory Diseases 3: 233-240.